Bernstein Says Sell SMMT: Why Summit Therapeutics Stock Could Drop More
Bernstein remains bearish on Summit, citing doubts about trial success and expecting weak results ahead.
/ 41 items
#MRK↓
Merck & Kelun’s sac-TMT Combo Cuts Lung Cancer Progression Risk by 65% vs Keytruda
Positive Phase 3 data shows Merck and Kelun’s sac-TMT combined with Keytruda reduced the risk of progression or death by 65% vs Keytruda alone in first-line PD-L1+ NSCLC.
Regeneron’s Melanoma Drug Crumbles Against Keytruda in Phase 3 Trial
Regeneron’s fianlimab + Libtayo combo showed 11.5 months PFS vs Keytruda’s 6.4 months in Phase 3 melanoma trial — but missed statistical significance. Analysts are “shaking heads” after the setback.
INBRX-106 + Keytruda Nearly Doubles Response Rate in First-Line Head & Neck Cancer
Inhibrx drug INBRX-106 with pembrolizumab boosted tumor response in head/neck cancer, showing higher shrinkage and immune activation.
Erasca Jumps on Merck Collaboration for RAS-Mutant Cancer Combo Trial
Erasca rises after teaming with Merck to test ERAS-0015 + Keytruda in RAS cancers, showing early tumor shrink but past safety concern.
$8 Billion Opportunity: Inhibrx’s Experimental Cancer Drug Draws Major Interest
Inhibrx is drawing strong interest from Merck and other big pharma for its experimental cancer drug INBRX-106 that could boost Keytruda. Potential $9B spin-off value.